In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) ...

After guideline changes, aspirin use dropped off overall, even for higher-risk patients in whom it might still be considered.

Decrease in use seen among older adults, adults with low ASCVD risk, but also among those with higher ASCVD risk ...

If this observation indeed holds true, and aspirin can stave off cancer or reduce the risk of recurrence, this familiar, age-old drug could offer a tantalizingly simple treatment. 1 Earlier studies ...

Recent studies have provided updated insights into the use of low-dose aspirin for primary prevention of CVD. The US Preventive Services Task Force (USPSTF) conducted a systematic review and ...

The prevalence of daily low-dose aspirin use fell significantly after the American College of Cardiology and the American ...

Study of 107,000 participants demonstrates regular aspirin use significantly reduces colorectal cancer risk, especially in individuals with unhealthy lifestyles ...

Safety: Aspirin was well-tolerated, with no major safety concerns reported. The ASCOLT trial showed that aspirin did not ...

Aspirin use in patients with PI3K-mutated colorectal cancer helped to reduce disease recurrence, highlighting the importance ...

Adjuvant treatment with aspirin is associated with a lower risk of recurrence at 3 years in CRC patients with PI3K pathway ...

Aspirin did not provide any clinical benefits in a cohort of patients with colorectal cancer who had no history of cardiovascular disease or stroke.

The ACCP guidelines recommend use of aspirin 325 mg for patients with AF who are considered to have a low stroke risk. Either aspirin 325 mg daily or warfarin with an international normalized ...